Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Illumina CEO survived Icahn's challenge by more than 2-to-1 margin

Published 05/30/2023, 06:40 PM
Updated 05/30/2023, 08:47 PM
© Reuters. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego,  California January 11, 2016. REUTERS/Mike Blake

By Svea Herbst-Bayliss

NEW YORK (Reuters) - Illumina Inc (NASDAQ:ILMN) CEO Francis deSouza survived a challenge to his board seat from activist investor Carl Icahn last week by securing more than twice the shareholder votes than the number his challenger received, the company said in a filing on Tuesday.

While the outcome of the vote was known, the tally had not been previously disclosed. It gives deSouza legitimacy to carry on after Icahn mustered enough shareholder support to oust Illumina's board chair John Thompson and install one of his board nominees, Andrew Teno.

Icahn tried to replace both deSouza and Thompson on the board and said he wants former Illumina CEO Jay Flatley to return to run the company. The company's share price lost 18.4% in the last 52 weeks.

A year ago deSouza was the company's top vote getter with 130,098,117 votes cast for him. This year he received 93,110,014 votes, beating out only Thompson and all three of Icahn's nominees.

Teno received 77,769,509 votes while Thompson received 45,091,516 votes. The two other Icahn nominees received the fewest votes.

Icahn criticized Illumina, including deSouza and Thompson, for its $7.1 billion acquisition of cancer test maker Grail. Illumina completed the deal over the objections of U.S. and European antitrust regulators, who are now trying to force the company to unwind it.

Illumina lost $50 billion in market value following the deal as investors fret it may be forced to divest Grail at a big loss.

Illumina has said it will expand its board from nine members to 11 and has interviewed chiefs of publicly traded companies with healthcare experience and chief financial officers of publicly traded companies with Wall Street experience to join. It will also elect a new board chair.

Activist investors are increasingly calling for top executives to be replaced, with Insightia data showing they pushed for the removal of personnel at 60 companies last year, a 46% jump from the year before and the highest amount since 2017.

Some CEOs who had activists join their board did not stay in the position for long. Unilever (NYSE:UL) Plc CEO Alan Jope, for example, announced plans to leave three months after hedge fund Trian Fund Management's Nelson Peltz joined the consumer giant's board last year. Brian Niccol took the reins at Chipotle Mexican Grill (NYSE:CMG) in early 2018 after one of Bill Ackman's lieutenants at Pershing Square Capital Management joined the board in late 2016.

© Reuters. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego,  California January 11, 2016. REUTERS/Mike Blake

Other CEOs have survived. Vicki Hollub remains Occidental Petroleum (NYSE:OXY)'s CEO after the company cut a deal with Icahn over board seats in 2020 and after Icahn cashed out two years later.

(This story has been corrected to say deSouza beat three, not two of Icahn's nominees, in paragraph 4)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.